Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Ibrutinib in Ibrutinib-Resistant CLL
NCT03513562Phase 2Active, not recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Mar 2019
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in chronic lymphocytic leukemia (CLL), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Mar 2019; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03513562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03513562.